Products

Our products

PregLem’s product pipeline focuses on women’s reproductive medicine with significant unmet medical needs that severely impact a patient’s quality of life and fertility.

ESMYA® (Ulipristal Acetate 5mg)

ESMYA® (ulipristal acetate 5mg)

ESMYA® (ulipristal acetate 5mg), is a first-in-class, oral selective progesterone receptor modulator (SPRM) which reversibly blocks the progesterone receptor in its target tissues (uterus, cervix, ovaries, hypothalamus) and acts as a potent, orally active antiprogestational agent. It is the first medical treatment for long term management of uterine fibroids. ESMYA® has successfully completed four Phase III clinical trials in Europe and has confirmed its efficacy and safety for the long term management of uterine fibroids and the treatment of symptomatic uterine fibroids in patients prior to surgery. Pivotal clinical studies have been published in peer reviewed journals such as New England Journal of Medicine and Fertility and Sterility.

PGL2001 (Steroid Sulfatase Inhibitor, STS-I)

PGL2001 is an oral, once-a-week steroid sulfatase inhibitor (STS-I) being developed for the management of endometriosis, including the relief of pain associated with the condition. Steroid sulfatases (STS) are enzymes expressed in tissues whose growth is oestrogen dependent. In these tissues, STS converts inactive oestrogens and androgens into their corresponding biologically active forms.

PGL2001 has the potential to be the first of a new class of products for the treatment of mild to moderate endometriosis and other benign gynaecological conditions.

Development stage: Phase IIa

PGL1001 (Somatostatin Antagonist, SST-ATG)

PGL1001 is a somatostatin antagonist (SST-ATG) with the potential to accelerate the recruitment of resting follicles from the ovarian follicular reserve. In this way, more follicles could be made responsive to gonadotrophin stimulation and could eventually produce an oocyte (egg). PGL1001 has the potential to become the first treatment for increasing the number of gonadotrophin-sensitive follicles in patients with a diminished or aging ovarian reserve, who undergo Assisted Reproductive Techniques (“ART”).